Middle East & Africa Pharmaceutical Manufacturing Market Size & Outlook
Global Market
Related Markets
MEA pharmaceutical manufacturing market highlights
- The MEA pharmaceutical manufacturing market generated a revenue of USD 8,968.0 million in 2023.
- The market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, conventional drugs (small molecules) was the largest revenue generating molecule type in 2023.
- Biologics & Biosimilars (Large Molecules) is the most lucrative molecule type segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 8,968.0 million |
| Market revenue in 2030 | USD 15,165.2 million |
| Growth rate | 7.8% (CAGR from 2024 to 2030) |
| Largest segment | Conventional drugs (small molecules) |
| Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
| Key market players worldwide | Roche Holding AG ADR, Novartis AG ADR, GlaxoSmithKline, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Johnson & Johnson, Sanofi SA, Eli Lilly and Co, AbbVie Inc, Thermo Fisher Scientific Inc, Wuxi AppTec Co Ltd, Samsung BioLogics, FUJIFILM Holdings Corp, Lonza Group Ltd, Catalent Inc, Jubilant Pharmova |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.8% of the global pharmaceutical manufacturing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 207,213.6 million by 2030.
The Middle East & Africa region has witnessed gradual developments in its pharmaceutical manufacturing industry, with more than 140 locally operational entities. The presence of global manufacturers in the region has boosted the market.
The top 10 companies, including Sanofi, Novartis, Pfizer, GSK, Novo Nordisk, MSD, and AstraZeneca, have captured 37% of the MEA market. Novo Nordisk's growth is major driven by Norditropin (somatropin), Victoza (liraglutide), and Saxenda (liraglutide).
In addition, increasing focus by regional government authorities on the wellbeing of their growing populations, coupled with advancements in healthcare services, is expected to propel the market over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Pharmaceutical Manufacturing Market Scope
Pharmaceutical Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
Middle East & Africa Pharmaceutical Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmaceutical Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Conventional Drugs (Small Molecules) was the largest segment with a revenue share of 63.05% in 2023.
Horizon Databook has segmented the Middle East & Africa pharmaceutical manufacturing market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
The Middle East & Africa region has witnessed gradual developments in its pharmaceutical manufacturing industry, with more than 140 locally operational entities. The presence of global manufacturers in the region has boosted the market.
The top 10 companies, including Sanofi, Novartis, Pfizer, GSK, Novo Nordisk, MSD, and AstraZeneca, have captured 37% of the MEA market. Novo Nordisk's growth is major driven by Norditropin (somatropin), Victoza (liraglutide), and Saxenda (liraglutide).
In addition, increasing focus by regional government authorities on the wellbeing of their growing populations, coupled with advancements in healthcare services, is expected to propel the market over the forecast period.
- Middle East & Africa Pharmaceutical Manufacturing Market Molecule Type Outlook (Revenue, USD Million , 2018-2030)
- Biologics & Biosimilars (Large Molecules)
- Conventional Drugs (Small Molecules)
- Middle East & Africa Pharmaceutical Manufacturing Market Drug Development Type Outlook (Revenue, USD Million , 2018-2030)
- Outsource
- In-house
- Middle East & Africa Pharmaceutical Manufacturing Market Formulation Outlook (Revenue, USD Million , 2018-2030)
- Tablets
- Capsules
- Injectables
- Sprays
- Suspensions
- Powders
- Other Formulations
- Middle East & Africa Pharmaceutical Manufacturing Market Routes of Administration Outlook (Revenue, USD Million , 2018-2030)
- Oral
- Topical
- Parenterals
- Inhalations
- Other Routes of Administration
- Middle East & Africa Pharmaceutical Manufacturing Market Therapy Area Outlook (Revenue, USD Million , 2018-2030)
- Cardiovascular Diseases
- Pain
- Diabetes
- Cancer
- Respiratory Diseases
- Other Diseases
- Middle East & Africa Pharmaceutical Manufacturing Market Prescription Requirements Outlook (Revenue, USD Million , 2018-2030)
- Prescription Medicines
- Over-the-counter (OTC) Medicines
- Middle East & Africa Pharmaceutical Manufacturing Market Age Type Outlook (Revenue, USD Million , 2018-2030)
- Children & Adolescents
- Adults
- Geriatric
- Middle East & Africa Pharmaceutical Manufacturing Market Sales Channel Outlook (Revenue, USD Million , 2018-2030)
- Retail
- Non-retail
Reasons to subscribe to Pharmaceutical Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmaceutical Manufacturing Market Outlook databook
- Our clientele includes a mix of Pharmaceutical Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Pharmaceutical Manufacturing Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Pharmaceutical Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Middle East Africa Pharmaceutical Manufacturing Market, 2018-2030 (US$M)
MEA pharmaceutical manufacturing market statistics, by molecule type, 2018-2030 (US$M)
